Home>Topics>Stocks>MAP Pharmaceuticals

MAP Pharmaceuticals MAPP

  1. All
  2. Commentary
  3. Headlines
    1. iBio Is Not The Partner Of Mapp's Ebola Drug

      Headlines

      Mon, 13 Oct 2014

      Friday in response to speculation that it may be a manufacture partner in the government's efforts to ramp up production of Mapp Biopharmaceuticals ' Ebola drug ZMapp . The stock price jumped another 70% in pre-market trading on Monday. However, a closer

    2. Ibio jumps on possible ZMapp production ramp

      Headlines

      Fri, 10 Oct 2014

      massive 13.2M shares in response to reports that it may be a player in the government's efforts to ramp up production of Mapp Biopharmaceuticals ' Ebola drug ZMapp . Ibio, working with Fraunhofer Center for Molecular Biotechnology, developed a plant

    3. U.S. maker of experimental Ebola drug ZMapp seeks to boost output

      Headlines

      Fri, 10 Oct 2014

      Oct 10 (Reuters) - California-based Mapp Biopharmaceutical Inc is making progress in efforts to boost production of the experimental Ebola treatment ZMapp, as the deadly virus continues to spread through West Africa and beyond, the company said Friday.

    4. UPDATE 1-Ebola drug trials to be fast-tracked in West Africa

      Headlines

      Tue, 23 Sep 2014

      LONDON, Sept 23 (Reuters) - Experimental Ebola drugs including compounds from Mapp Biopharmaceutical, Sarepta and Tekmira will be tested in affected West African states for the first time in a bid to fast-track trials, the Wellcome Trust said on Tuesday.

    5. Ebola drug trials to be fast tracked in Africa

      Headlines

      Tue, 23 Sep 2014

      2M ($5.25M) grant to fund clinical trials in West Africa for several experimental Ebola drugs, including products from Mapp Biopharmaceutical, Serepta Therapeutics (NASDAQ: SRPT ) and Tekmira (NASDAQ: TKMR ). The charity's Director, Jeremy

    6. Ebola drug trials to be fast-tracked in West Africa

      Headlines

      Tue, 23 Sep 2014

      LONDON, Sept 23 (Reuters) - Several experimental Ebola drugs, including compounds from Mapp Biopharmaceutical, Sarepta and Tekmira, will be tested in West Africa for the first time in a bid to fast-track trials, the Wellcome Trust charity said on Tuesday.

    7. Allergan Will Control Migraine Portfolio Through Planned MAP Acquisition

      Commentary

      Wed, 23 Jan 2013

      Allergan AGN announced it intends to acquire MAP Pharmaceuticals for approximately $950 million. The news is not particularly surprising because both companies formed a partnership in 2011 for

    8. MAP Pharma shares dive after FDA rejects migraine treatment

      Headlines

      Tue, 27 Mar 2012

      (Reuters) - Shares of MAP Pharmaceuticals Inc fell by a third in premarket trade on Tuesday, after health regulators rejected its orally inhaled treatment for migraine, but analysts remain...

    9. Dropping Coverage of MAP Pharmaceuticals

      Commentary

      Mon, 29 Aug 2011

      We are no longer providing equity research on MAP Pharmaceuticals MAPP . We provide broad coverage of more than 1,700 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.

    10. MAPP Transmission Project Delay In Line With Our Expectations for Pepco

      Commentary

      Fri, 19 Aug 2011

      the projected in-service date for the MAPP transmission project by four to six years ..... be the best-case scenario. Given that MAPP promises 12.8% federally approved returns ..... violations earlier than 2019, making the MAPP transmission project unnecessary at this

    « Prev123Next »
    Content Partners